Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Revenio Group Corporation’s financial reporting and Annual General Meeting in 2026

Revenio Group
Download the release

Revenio Group Corporation | Stock Exchange Release | October 30, 2025 at 09:05:00 EET

Revenio Group Corporation will publish the following financial reports in 2026:

  • Financial Statements Bulletin for the year 2025 on Wednesday, February 11, 2026
  • Annual reporting package 2025 will be published at the latest during week 13 in 2026
  • Interim report 1-3/2026 on Tuesday, April 28, 2026
  • Half-year financial report 1-6/2026 on Thursday, August 6, 2026
  • Interim report 1-9/2026 on Thursday, October 29, 2026

The financial statements bulletin, half-year report, and interim reports will be published at approximately 9.00 am Finnish time on the above dates.

The Annual General Meeting is planned to be held on Thursday, April 15, 2026. The Board of Directors will convene the meeting.

A shareholder who wishes to include an item on the agenda of the Annual General Meeting shall submit the request in writing to the company's Board of Directors by February 23, 2026. Such requests, including the reasoning or a resolution proposal, can be submitted to the address: Revenio Group Corporation / Board of Directors, Härkähaankuja 7, FI-01730 Vantaa, Finland.

For further information, please contact
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Key media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2024, the Group’s net sales totaled EUR 103.5 million, with an operating profit of EUR 25.0 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments


Revenio Group Corporation’s financial reporting and Annual General Meeting in 2026

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.